Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI
* Results showed partial response being confirmed in 7 out of 42 patients * Partial response was observed in 3 out of 8 patients who were previously treated by immunotherapy SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in...
Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial
* Positive primary endpoint result of objective response rate (ORR) from the planned interim analysis of Phase II trial in advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJ). * Top-line data of the final analysis from Phase II to be announced in the second half of next year. S...
Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial
SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- Genome & Company (CEO: Pae, Jisoo), a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim...
Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients
SEOUL, South Korea, March 3, 2022 /PRNewswire/ -- Genome and Company (KOSDAQ: 314130, CEO∙CTO: Jisoo Pae∙Hansoo Park), a leading global microbiome anti-cancer drug development company, announced it has entered into a first Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a trad...
Genome and Company signs second clinical trial collaboration and supply agreement (Phase 2) with Merck KGaA, Darmstadt, Germany and Pfizer for immuno-oncology microbiome study
* Genome and Company expands collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for further clinical combination study of GEN-001 in gastric cancers * Establishment of the efficient "clinical development strategy" for the global immuno-oncology microbiome treatment SEOUL, South Korea,...
Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients
SEOUL, South Korea, Feb. 24, 2021 /PRNewswire/ -- Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading immuno-oncology firm, and Debiopharm, a Swiss-based biopharmaceutical company specializing in oncology and infectious diseases, today announced having entered into a research ...
Genome & Company announces first patient dosed in Phase 1/1b study of GEN-001, an immuno-oncology microbiome therapeutic, in combination with avelumab
* The first microbiome oncology therapeutic candidate developed by an Asia -based biotech successfully initiatesphase 1/1b clinical trial in the US, six months after its IND went into effect. * The first patient enrolled and treated at OHSU (Oregon Health & Science University Knight Cancer In...
Genome & Company receives FDA IND clearance for GEN-001, its first anti-cancer microbiome therapeutic
SEOUL, South Korea, April 20, 2020 /PRNewswire/ -- Genome & Company (KONEX: 314130), a biotechnology company developing innovative therapeutics in immune-oncology, announced today thatthe United States (US) Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) applic...
Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer
SEOUL, South Korea, Jan. 14, 2020 /PRNewswire/ -- Genome & Company (KONEX: 314130) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt,Germany and Pfizer Inc. to evaluate the safety, tolerability, biological and clinical ...
